Clinical Trials Logo

Gastrointestinal Microbiome clinical trials

View clinical trials related to Gastrointestinal Microbiome.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06359808 Not yet recruiting - Colitis, Ulcerative Clinical Trials

Clinical Characteristics of Sleep Disorders in Patients With Ulcerative Colitis

Start date: April 2024
Phase:
Study type: Observational

Ulcerative colitis(UC) is one of the two main forms of inflammatory bowel disease(IBD), which seriously affects the quality of life of patients. Previous studies have demonstrated that more than 60% of IBD patients have sleep disorders, which is emerging as an important risk factor for disease recurrence and poor prognosis. However, the mechanisms by which sleep disorders regulates the occurrence and development of IBD remain undefined. This study aims to explore the clinical characteristics of ulcerative colitis patients with sleep disorders based on the microbiota-gut-brain axis, to analyze the effects of sleep disorders on autonomic nervous function, gut microbiota, and metabolites in UC patients.

NCT ID: NCT06332898 Not yet recruiting - Healthy Aging Clinical Trials

The Effects of a Nutritional Supplement on Nutrient Status and Quality of Life

Start date: March 31, 2024
Phase: N/A
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled study of N=120 apparently healthy men and women. The purpose of this study is to assess the effect of a novel dietary supplement on blood markers of nutrient status, gut microbiome, and overall quality of life.

NCT ID: NCT06207136 Not yet recruiting - Parkinson Disease Clinical Trials

Microbiome and Diet in Parkinson's Disease

PD-Diet
Start date: June 3, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot study is to examine the feasibility and effects of an 18-month intervention diet compared to an active control diet (standard diet) in those living with Parkinson's Disease (PD), without dementia. Research has shown that eating components of Mediterranean diets are associated with a 30% lower risk to develop PD and a 40% lower mortality rate in those living with PD. Diet may influence the gut and microbiomes, thus may affect PD risk and progression. This study will examine how easy it will be to adhere to a certain type of diet for 18 months and what changes may occur in the gut microbiome and in PD symptoms on a specific diet during that time. The study will involve in-person study visits at UBC as well as online diet coaching sessions and online group cooking classes over Zoom. This is a randomized study, meaning that participants will be assigned by chance to either the Mediterranean-style diet group or the standard diet group for the duration of the 18 months. This pilot study will also examine recruitment rates and retention, in order to prepare for a larger future study.

NCT ID: NCT06126094 Not yet recruiting - Clinical trials for Gastrointestinal Microbiome

Benefits of Alcoholic Hangover Medicine

BLAM
Start date: October 31, 2023
Phase: N/A
Study type: Interventional

Myrkl is advertised as a dietary supplement for use before alcohol consumption that is effective in prevention of side effects during the next day. With this research, the investigators want to determine the impact of the mentioned dietary supplement on the intestinal microbiome. For this purpose, the research was designed in three phases before, during and after the research as a double blind trial. In doing so, the subjects take a stool sample before and after the intervention and during the intervention, fill out questionnaires and undergo cognitive tests. At the same time, they give a blood sample after the intervention. After the results of the analysis are due, the researchers enter the data into the for that the predicted Access table (rel. representation of genera/genera/species, average results by questionnaires). The entered data is processed as part of statistical analysis.

NCT ID: NCT06021535 Not yet recruiting - Aortic Stenosis Clinical Trials

Involvement of the Gut Microbiota in Calcified Aortic Stenosis

Gut-CAS
Start date: January 1, 2024
Phase:
Study type: Observational

Calcific aortic stenosis (CAS) is a disease characterized by progressive calcification of the aortic valve, obstructing the passage of blood from the left ventricle into the general circulation. It is the most frequent cause of valve disease in the elderly. To date, no means of preventing the disease has been discovered, and the only treatment available is valve replacement during cardiac surgery, or percutaneous implantation of a valve prosthesis when the narrowing becomes severe and causes symptoms. The intestinal flora or microbiota, the reservoir of all the microorganisms in the gut, is implicated in numerous diseases, particularly of the intestine. But to date, no study has established a link between CAS and microbiota. The intestinal microbiota acts through molecules produced by itself or the host and passing into the bloodstream. In the pathophysiology of CAS, the valve leaflets are breached and do not heal. These molecules can enter and have beneficial or deleterious effects, in particular promoting calcification of aortic valve cells. Concrete objectives: Improve understanding of calcific aortic stenosis in humans Study the composition of intestinal flora in patients with aortic stenosis and compare it with healthy subjects Study the molecules in the intestinal flora likely to be involved in the development of aortic stenosis in humans.

NCT ID: NCT05364736 Not yet recruiting - Hypertension Clinical Trials

Effect of Prebiotics on Blood Pressure Management

Start date: October 17, 2022
Phase: N/A
Study type: Interventional

This survey is designed to investigate the effect of highland barley β-glucan supplementation on the regulatory of blood pressure, gut microbiota and cardiovascular risk fators in subjects with hypertention.

NCT ID: NCT04947930 Not yet recruiting - Colorectal Cancer Clinical Trials

Fecal Metagenomics and Metabolomics Analyses to Identify Potential Screening Biomarkers for Colorectal Polyps and Cancer in Chinese Population

Start date: July 2021
Phase:
Study type: Observational

Many previous studies had revealed that gastrointestinal microbiome is changed compositionally and ecologically in patients with colorectal cancer comparing with healthy population. These finding provide us with a new sight to take advantage of gut microbiota. The current study aims to explore new potential biomarkers for early screening and prognostic prediction of colorectal cancer and colorectal polyps by analyzing metagenomics and metabolomics of gut microbiota.

NCT ID: NCT04189393 Not yet recruiting - Colorectal Cancer Clinical Trials

Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery

MA-PPING
Start date: January 1, 2020
Phase:
Study type: Observational

The MA-PPING is a multicenter prospective observational study that includes patients undergoing surgery for gastrointestinal cancer. The study aims to map the oral and gut microbiome of patients diagnosed with pancreatic, esophageal or colorectal cancer during their surgical patient journey from the moment of diagnosis until full recovery (three months after surgery).

NCT ID: NCT03569137 Not yet recruiting - Clinical trials for Gastrointestinal Microbiome

Post-Ibrutinib Colitis and Intestinal Microbiota

COLMI
Start date: August 1, 2018
Phase:
Study type: Observational

Identify gut microbiome biomarkers associated with colitis in patients treated with targeted therapy in hematology